证券代码：600866 证券简称：星湖科技 公告编号：临 2023-030 广东肇庆星湖生物科技股份有限公司 2023 年度上半年主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 广东肇庆星湖生物科技股份有限公司（以下简称"公司"）根据 上海证券交易所《上市公司行业信息披露指引第十四号——食品制造 （2022 年修订）》的要求，现将公司 2023 年上半年度主要经营数据 披露如下： 一、主营业务收入情况 单位：万元 币种：人民币 | 产品类别 | 本期主营业务收入 | | | --- | --- | --- | | 食品添加剂 | | 226,753.16 | | 饲料添加剂 | | 534,470.70 | | 生化原料药及制剂 | 7,840.77 | | | 医药中间体 | | 14,141.01 | | 有机肥料 | | 14,800.69 | | 合计 | | 798,006.33 | 三、 地区分布情况 单位：万元 币种：人民币 | | 区域 | 本期主营业务收入 | | --- | --- | ...

证券代码：600866 证券简称：星湖科技 公告编号：临 2023-032 广东肇庆星湖生物科技股份有限公司 关于召开 2023 年第二次临时股东大会的通知 (一) 股东大会类型和届次 2023 年第二次临时股东大会 召开的日期时间：2023 年 9 月 13 日 14 点 00 分 召开地点：广东省肇庆市工农北路 67 号公司会议室 (五) 网络投票的系统、起止日期和投票时间。 股东大会召开日期：2023年9月13日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 9 月 13 日 至 2023 年 9 月 13 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间 ...

股票代码：600866 股票简称：星湖科技 编号：临 2023-031 广东肇庆星湖生物科技股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法 律责任。 重要内容提示： ●拟续聘的会计师事务所名称：信永中和会计师事务所（特殊普通合伙） 一、拟续聘请会计师事务所的情况说明 公司2021年年度股东大会审议通过聘请信永中和为公司2022年度的 审计机构，聘期一年。在 2022 年度的审计工作中，信永中和参与年审的 人员具备实施审计工作所需的专业知识和相关的执业证书，在审计过程 中，遵循独立、客观、公正的职业准则，顺利完成了公司 2022 年度财务 报告及内部控制审计工作，表现了良好的职业操守和业务素质。 二、拟聘任会计师事务所的基本情况 （一）机构信息 1、基本信息 名称：信永中和会计师事务所（特殊普通合伙） 成立日期：2012 年 3 月 2 日 组织形式：特殊普通合伙企业 注册地址：北京市东城区朝阳门北大街 8 号富华大厦 A 座 8 层 首席合伙人：谭小青 广东肇庆星湖生物科技股份有限公司（以下简 ...

证券代码：600866 证券简称：星湖科技 公告编号：临 2023-028 广东肇庆星湖生物科技股份有限公司 董事会会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 经全体董事审议表决，通过了以下议案： 1.《关于 2023 年半年度报告（全文及摘要）的议案》 1 具 体 内 容 详 见 同 日 刊 登 在 上 海 证 券 交 易 所 网 站 （http://www.sse.com.cn）的《广东肇庆星湖生物科技股份有限公 司 2023 年半年度报告》及《广东肇庆星湖生物科技股份有限公司 2023 年半年度报告摘要》。 表决结果为 8 票同意，0 票反对，0 票弃权。 2.《关于续聘公司审计机构的议案》 同意续聘信永中和会计师事务所（特殊普通合伙）为公司的会计 和内部控制审计机构，聘期一年，审计费用提请股东大会授权经营层 根据公司实际业务和市场行情等因素与审计机构协商议定后报董事 会审议。本议案需提交公司股东大会审议（详见同日临 2023-031《关 于续聘会计师事务所的公告》）。 表决结果为 8 票同意，0 票 ...

股票代码：600866 股票简称：星湖科技 公告编号：临 2023-029 广东肇庆星湖生物科技股份有限公司 监事会会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 一、监事会会议召开情况 广东肇庆星湖生物科技股份有限公司（以下简称"公司"）第十届 监事会第十九次会议于 2023 年 8 月 25 日召开，会议应参会监事 3 人， 实际参会监事 3 人，其中监事张磊以通讯方式参加本次会议。会议由 监事会主席吴柱鑫先生主持。会议的召集、召开符合有关法律、法规 和本公司章程的规定。 二、监事会会议审议情况 会议审议并一致表决通过以下议案： 同意提名张磊女士、许荣丹女士为公司新一届监事会非职工代表 监事候选人。监事任期 3 年，自股东大会选举通过之日起计算。本议 案须提交公司股东大会审议，股东大会将对上述被提名人选以累积投 票制进行表决（候选人简历见附件）。 （一）《关于 2023 年半年度报告（全文及摘要）的议案》 公司监事会关于 2023 年半年度报告的审核意见： 1.公司 2023 年半年度报告的编制符合法律、法 ...

2023 年第一季度报告 证券代码：600866 证券简称：星湖科技 广东肇庆星湖生物科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 上年同期 | | 本报告期比上 年同期增减变 动幅度(%) | | --- | --- | --- | --- | --- | | | | 调整前 | 调整后 | 调整后 | | 营业收入 | 4,163,243,647.49 | 277,656,519.86 | 4,170,645,177.54 | -0.18 | | 归属于上市公司股 东的净 ...

重要内容提示： 广东肇庆星湖生物科技股份有限公司（以下简称"公司"）已于 2023 年 3 月 28 日发布公司 2022 年度报告，为便于广大投资者更全 面深入地了解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 04 月 25 日 上午 11:00-12:00 举行 2022 年度业绩说明会， 就投资者关心的问题进行交流。 证券代码：600866 证券简称：星湖科技 公告编号：临 2023-019 广东肇庆星湖生物科技股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 会议召开时间：2023 年 04 月 25 日(星期二) 上午 11:00- 12:00 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 04 月 18 日(星期二) 至 04 月 24 日(星期 一)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目 ...

Financial Performance - In 2022, the company's operating revenue reached RMB 17.49 billion, an increase of 329.51% compared to RMB 4.07 billion in 2021[21]. - The net profit attributable to shareholders was RMB 608.33 million, up 299.85% from RMB 152.14 million in the previous year[21]. - The net cash flow from operating activities was RMB 1.66 billion, representing an increase of 888.42% compared to RMB 168.20 million in 2021[21]. - Basic earnings per share increased by 171.58% to CNY 0.5122 in 2022 from CNY 0.1886 in 2021[23]. - The weighted average return on equity rose by 6.26 percentage points to 13.46% in 2022, compared to 7.20% in 2021[23]. - The company achieved a sales revenue of 17.486 billion yuan in 2022, representing a year-on-year growth of 329.51%[32]. - The net profit attributable to shareholders reached 608 million yuan, with a year-on-year increase of 299.85%[32]. - The total revenue for the year 2022 was 18,800 million, with a net profit of 1,095.17 million[128]. Assets and Liabilities - The total assets at the end of 2022 amounted to RMB 15.99 billion, a slight increase of 0.86% from RMB 15.86 billion at the end of 2021[22]. - The total assets as of December 31, 2022, amounted to 15.998 billion yuan, with total liabilities of 9.069 billion yuan, resulting in a debt-to-asset ratio of 56.69%[32]. - The company reported cash and cash equivalents of CNY 205,263,422.55, which includes various guarantees and deposits[88]. - The total fixed assets were valued at CNY 4,404,583,006.49, primarily secured by loans[88]. Mergers and Acquisitions - The company completed the acquisition of 99.22% of Yipin Biological on November 22, 2022, significantly impacting its financial performance[57]. - The acquisition of 99.22% of Yipin Biological significantly enhanced the company's asset scale and profitability, facilitating a leap in development[33]. - The company completed the acquisition of 99.22% of Yipin Biotechnology, making it a subsidiary[100]. - The company approved a proposal for issuing shares and cash to acquire assets and raise matching funds, indicating a significant asset restructuring plan[138]. Market and Industry Trends - The global demand for monosodium glutamate is projected to grow at an annual rate of approximately 1.4% over the next five years, indicating a stable market for food additives[40]. - The feed additive industry is benefiting from national policies that promote the healthy development of large enterprises, with significant advancements in biotechnology and agricultural modernization[38]. - The company aims to become a leader in the Chinese bio-fermentation industry by focusing on three main sectors: food and feed additives, and pharmaceuticals, while enhancing its industrial layout[115]. Risks and Challenges - The management has outlined potential risks and unfavorable factors that may affect future operations in the report[7]. - The company faces operational management risks due to increased responsibilities after the acquisition of Yipin Bio, which may complicate its management structure[117]. - Market competition risks are heightened as major enterprises actively pursue vertical and horizontal expansions, potentially leading to a decrease in market share and profitability if the company fails to adapt[117]. - Financial risks are present due to a relatively high debt ratio post-restructuring, which may limit the company's ability to finance further production expansion[118]. Research and Development - The company has established a research and development strategy that supports sustainable high-quality development, with significant reductions in product costs[34]. - Research and development expenses reached RMB 106,065,780.88, also reflecting the consolidation of Yipin Biological[55]. - The company is investing heavily in R&D for new technologies, with an allocation of 5.83 million towards innovative projects[128]. Environmental Responsibility - The company has established a complete set of environmental protection facilities, ensuring a 100% operational rate[171]. - The company achieved stable pollutant discharge levels in 2022, meeting industry and national standards[164]. - The company has invested in various environmental technology upgrades, including wastewater and waste gas treatment projects, to enhance pollution control efforts[184]. Corporate Governance - The company has a total of 12 board members and supervisors, with 5 being independent directors[127]. - The board of directors held 9 meetings during the year, with all members attending in person[142]. - The independent directors participated fully in board meetings, with no absences recorded[141]. Social Responsibility - The company has committed to social responsibility initiatives, contributing a total of 3.4742 million yuan to various charitable projects, including education and poverty alleviation[188]. - The company has established rural economic cooperatives to strengthen collective economic growth in key villages[192]. - The company has invested a total of 30 million yuan in rural revitalization work funding in 2022, which includes 7 million yuan for streetlight projects and 17 million yuan for the first phase of the collective economic project in Jiyi Village[193].

Financial Performance - The company's operating revenue for Q3 2022 was ¥352,003,207.03, representing a year-on-year increase of 34.43% compared to ¥261,854,216.31 in the same period last year[8]. - Net profit attributable to shareholders for Q3 2022 reached ¥38,810,913.33, a significant increase from ¥-7,298,336.71 in the same period last year, marking an increase of 104.50% year-to-date[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥30,388,714.13, up 105.92% from ¥-9,771,788.03 in the same period last year[8]. - Total operating revenue for the first three quarters of 2022 reached ¥982,756,979.74, an increase of 14.3% compared to ¥859,617,648.57 in the same period of 2021[33]. - Net profit for the first three quarters of 2022 was ¥117,248,561.32, compared to ¥57,335,596.98 in 2021, indicating a significant increase of 104.5%[35]. - Basic earnings per share for Q3 2022 were ¥0.0525, up from ¥0.0048 in the same period last year, reflecting a year-to-date increase of 104.51%[8]. - The company reported a basic earnings per share of ¥0.1587, up from ¥0.0776 in the previous year, marking a 104.0% increase[35]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥132,178,961.91, a substantial increase of 187.36% compared to ¥45,998,317.29 in the same period last year[8]. - Operating cash inflow for the first three quarters of 2022 reached CNY 905,124,796, an increase of 24.3% compared to CNY 728,339,940 in the same period of 2021[39]. - Cash outflow for purchasing goods and services was CNY 519,894,473.11, up from CNY 393,603,287.43, reflecting a 32.1% increase year-over-year[39]. - The ending balance of cash and cash equivalents increased to CNY 280,999,453.43 from CNY 219,109,783.36, representing a growth of 28.2%[42]. - The company's cash and cash equivalents stood at 280,999,453.43 RMB, compared to 231,033,037.97 RMB at the end of 2021, reflecting a growth of approximately 21.6%[26]. - Total assets at the end of the reporting period were ¥2,505,830,701.27, representing a 2.56% increase from ¥2,473,349,312.72 at the end of the previous year[8]. Shareholder Information - As of the end of the reporting period, the total number of common shareholders was 44,367, with the largest shareholder, Guangdong Guangxin Holdings Group Co., Ltd., holding 149,422,420 shares, representing 20.22% of the total[19]. - Shareholders' equity attributable to the parent company increased to ¥1,863,167,856.87, a rise of 6.73% from ¥1,775,607,578.86 at the end of the previous year[8]. - The total equity attributable to shareholders reached ¥1,863,167,856.87, compared to ¥1,745,617,972.10, an increase of 6.7%[33]. Market and Operational Insights - The increase in revenue was primarily driven by strong market demand for the company's main products, nucleotides and certain raw materials, leading to a rise in both sales volume and price[15]. - The company reported a significant improvement in gross profit due to favorable market conditions, resulting in a strong growth in operating performance[15]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[38]. Liabilities and Expenses - Total liabilities amounted to ¥642,662,844.40, a decrease from ¥697,741,733.86, indicating a reduction of 7.9%[33]. - Non-current liabilities totaled ¥296,726,393.74, up from ¥261,428,086.72, reflecting a growth of 13.5%[33]. - Research and development expenses increased to ¥54,441,204.85 from ¥46,032,373.88, representing a growth of 18.5%[33]. Acquisition Plans - The company is in the process of acquiring 99.22% of Ningxia Yipin Biotechnology Co., Ltd., with the transaction pending approval from the China Securities Regulatory Commission[22]. - The company plans to issue shares to raise funds to support the acquisition, pending regulatory approval, which introduces uncertainty regarding the timing and success of the transaction[22].

Financial Performance - The company's operating revenue for the first half of 2022 was RMB 630,753,772.71, representing a 5.52% increase compared to RMB 597,763,432.26 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was RMB 78,437,647.99, a 21.36% increase from RMB 64,633,933.69 in the previous year[20]. - The net cash flow from operating activities was RMB 34,479,030.27, a significant recovery from a negative cash flow of RMB -11,942,434.23 in the same period last year[20]. - Basic earnings per share for the first half of 2022 were RMB 0.1061, up 21.26% from RMB 0.0875 in the same period last year[20]. - The weighted average return on net assets increased to 4.39%, up 0.59 percentage points from 3.80% in the previous year[20]. - The company reported a net profit after deducting non-recurring gains and losses of RMB 72,565,857.53, which is a 21.41% increase from RMB 59,769,715.12 in the same period last year[20]. - The total profit for the first half of 2022 was RMB 80,002,273.37, an increase from RMB 68,370,619.60 in the first half of 2021[132]. - Tax expenses decreased to RMB 1,564,625.38 from RMB 3,736,685.91, contributing to higher net profit[132]. Revenue Breakdown - In the first half of 2022, the company's sales revenue from food additives reached 442 million RMB, representing a year-on-year increase of 21.49%, accounting for 71.58% of total operating income[28]. - The sales revenue from chemical raw materials and intermediates was 176 million RMB, showing a year-on-year decrease of 22.12%, which accounted for 28.42% of total operating income[28]. - The company achieved a sales revenue of 631 million RMB, an increase of 32.99 million RMB, representing a growth of 5.52% year-on-year[32]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 2,438,475,427.42, showing a slight decrease of 0.20% from RMB 2,443,359,705.96 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company increased to RMB 1,824,361,971.23, reflecting a growth of 4.51% from RMB 1,745,617,972.10 at the end of the previous year[20]. - Current liabilities totaled CNY 436,313,647.14, an increase of 25.3% from CNY 347,935,129.98 in the previous period[120]. - Non-current liabilities amounted to CNY 261,428,086.72, showing a slight increase of 1.4% from CNY 266,178,326.21[120]. - Total liabilities reached CNY 697,741,733.86, reflecting a decrease of 12.0% compared to CNY 614,113,456.19[120]. Research and Development - The company is focusing on the development of new amino acid raw materials, aiming for breakthroughs in product innovation and optimizing existing production processes[35]. - Research and development expenses increased to RMB 38,529,581.09, up from RMB 31,647,072.30, indicating a focus on innovation[129]. - The company aims to enhance its R&D capabilities and accelerate the application of new products and technologies through industry-academia collaboration[52]. Environmental Commitment - The company is committed to enhancing safety and environmental standards, implementing various safety measures and promoting green development initiatives[35]. - The company has established a comprehensive environmental protection system with a 100% operational rate for pollution control facilities[66]. - The company actively implemented clean production measures, achieving stable operation of pollution control facilities across all subsidiaries[66]. - The company has developed emergency response plans for environmental incidents, which have been filed with local environmental authorities[70]. - The company’s emissions of CODcr were controlled at 60.61 tons, well below the allowed total of 226.24 tons per year[65]. Strategic Initiatives - The company has initiated a major asset restructuring plan, aiming to acquire 99.22% of Yipin Biological's shares, which could significantly impact its financial structure and profitability[36]. - The company is actively pursuing market expansion and has strengthened its marketing network, establishing long-term strategic partnerships with major domestic and international enterprises[31]. - The company plans to continue its market expansion and strategic acquisitions in the future[106]. Legal and Compliance Issues - The company is currently involved in a patent lawsuit with CJ First Sugar Co., which claims infringement on its I+G and IMP products, with potential compensation claims of RMB 20 million[52]. - The company has not disclosed any updates on employee stock ownership plans or other incentive measures[62]. - The company has not provided guarantees to shareholders, actual controllers, or related parties during the reporting period[102]. Financial Management - The company has established a financial shared service center to enhance financial management capabilities across production, sales, and inventory[52]. - The company has applied to the China Securities Regulatory Commission to resume the review of the asset acquisition and fundraising matters[106]. - The total amount of guarantees provided by the company, including those to subsidiaries, was 38,398.96 million RMB, accounting for 21.05% of the company's net assets[102].